Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation

Figure 4

KML-B-treated BMDCs suppressed the E.G7 tumor size in mouse models. C57BL/6 mice were injected subcutaneously (flank site) with 1 × 10⁵ E.G7 cells and then injected intravenously (tail vein) with PBS, untreated DCs (imDC), DCs pulsed with OVA_257−264 (OVA-DC), or KML-B (500 ng/ml)-treated DCs pulsed with OVA_257−264 (OVA-KML-B-DC) on days 0, 2, and 4 after tumor challenge ((a), mice/group). ^A,B,CThe means not sharing a common letter are significantly different among groups at by Ducan’s multiple-range test. (b) E.G7 tumor-inoculated mice were injected intravenously with PBS, untreated DCs (imDC), DCs pulsed with OVA_257−264 (OVA-DC), or KML-B (500 ng/ml)-treated DCs pulsed with OVA_257−264 (OVA-KML-B-DC) on days 0 and 7. On day 14, splenocytes were harvested and treated with OVA_257−264 (1 μg/ml) for 24 hours ( mice/group). Cytokines were measured from the supernatant. ^A,B,C,DThe means not sharing a common letter are significantly different among groups at by Ducan’s multiple-range test.

(a)

(b)